Developments in liposomal drug delivery systems

Bibliography

• BANGHAM AD, STANDISH MM, WATKINS JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. Mol. Biol. (1965) 13:238–252.
   Web of Science ®Google Scholar
• WATSON J: fedi Apprentice: The Hidden Past. Scholastic, Inc., NY (1999).
   Google Scholar
• NEEDHAM D: The mechanochemistry of lipid vesicles examined by micropipet manipulation techniques. In: Vesicles. M Rosoff (Ed.), Surfactant Science series, Vol. 62, Marcel Dekker, Inc., NY (1996):373–444.
   Google Scholar
• CULLIS PR, FENSKE DB, HOPE MJ: Physical properties and functional roles of lipids in membranes. In: Biochemistry of Lipids, Lipoproteins and Membranes. DE Vance, J Vance (Eds.), Elsevier, Amsterdam (1996):1–33.
   Google Scholar
• ••Review of the physical properties andfunctional roles of lipids in membranes.
   Google Scholar
• KIRBY C, CLARKE J, GREGORIADIS G: Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186:591–598.
   Google Scholar
• BLOOM M, EVANS E, MOURITSEN OG: Physical properties of the fluid lipid-bilayer component of cell membranes: a perspective. Quart. Rev. Biophys. (1991) 24:293–397.
   PubMed Web of Science ®Google Scholar
• CULLIS PR, DE KRUIJFF B: Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim. Biophys. Acta (1979) 559:399–420.
   PubMed Web of Science ®Google Scholar
• LINDBLOM G, RILFORS L: Nonlamellar phases formed by membrane lipids. Adv. Colloid Interface Sci. (1992) 41:101–125.
   PubMed Web of Science ®Google Scholar
• CULLIS PR, DE KRUIJFF B: The polymorphic phase behaviour of phosphatidylethanolamine of natural and synthetic origin: A 31P NMR study. Biochim. Biophys. Acta (1978) 513:31–42.
   PubMed Web of Science ®Google Scholar
• MADDEN TD, CULLIS PR: Stabilization of bilayer structure for unsaturated phosphatidylethanolamines by detergents. Biochim. Biophys. Acta (1982) 684:149–153.
   PubMed Web of Science ®Google Scholar
• LITZINGER DC, HUANG L: Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. Biochim. Biophys. Acta (1992) 1113:201–227.
   PubMed Web of Science ®Google Scholar
• HOLLAND JW, CULLIS, PR, MADDEN TD: Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids. Biochemistry (1996) 35:2610–2617.
   PubMed Web of Science ®Google Scholar
• HAFEZ IM, ANSELL S, CULLIS PR: Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. Biophys J(2000) 79:1438–1446.
   PubMed Web of Science ®Google Scholar
• LEWIS RNAH, MCELHANEY RN: Surface charge markedly attenuates the nonlamellar phase-forming propensities of lipid bilayer membranes: calorimetric and P-31-nuclear magnetic resonance studies of mixtures of cationic, anionic, and zwitterionic lipids. Biophys. J. (2000) 79:1455–1464.
   PubMed Web of Science ®Google Scholar
• HAFEZ IM, MAURER N, CULLIS PR: On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Therapy (2001) 8:1188–1196.
   PubMed Web of Science ®Google Scholar
• TORCHILIN VP, ZHOU F, HUANG L: pH-sensitive liposomes. J. Lip osome Res. (1993) 3:201–255.
   Google Scholar
• DRUMMOND DC, ZIGNANI M, LEROUX J: Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res. (2000) 39:409–460.
   PubMed Web of Science ®Google Scholar
• HAFEZ I, CULLIS PR: Roles of lipid polymorphism in intracellular delivery. Adv. Drug Del. Rev. (2001) 47:139–148.
   PubMed Web of Science ®Google Scholar
• ••This review outlines the molecular basis forthe polymorphic phase behaviour of lipids and highlights some of the uses of non-bilayer lipids in the preparation of lipid-based delivery systems.
   Google Scholar
• KIRPOTIN D, HONG K, MULLAH N, PAPAHADJOPOULOS D, ZALIPSKY S: Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. (1996) 388:115–118.
   PubMed Web of Science ®Google Scholar
• GENNIS RB: Interactions of small molecules with membranes: Partitioning, permeability, and electrical effects. In: Biomembranes. Molecular Structure and Function. Springer Verlag, NY (1989):235–269.
   Google Scholar
• DE GIER J, MANDERSLOOT JG, VANDEENEN LLM: Lipid composition and permeability of liposomes. Biochim. Biophys. Acta (1968) 150:666–675.
   PubMed Web of Science ®Google Scholar
• PAPAHADJOPOULOS D, COWDEN M, KIMELBERG H: Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim. Biophys. Acta (1973) 330:8–26.
   PubMedGoogle Scholar
• MCLEAN LR, PHILLIPS MC: Kinetics of phosphatidylcholine and lysophosphatidylcholine exchange between unilamellar vesicles. Biochemistry (1984) 23:4624–4630.
   PubMed Web of Science ®Google Scholar
• NICHOLS JW: Intermembrane and transbilayer transfer of phospholipids. In: Phospholipids Handbook. G Cevc (Ed.), Marcel Dekker, Inc., NY (1993):663–685.
   Google Scholar
• SILVIUS JR, LEVENTIS R: Spontaneousinterbilayer transfer of phospholipids: dependence on acyl chain composition. Biochemistry (1993) 32:13318–13326.
   PubMed Web of Science ®Google Scholar
• SILVIUS JR, ZUCKERMANN MJ: Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion. Biochemistry (1993) 32:3153–3161.
   PubMed Web of Science ®Google Scholar
• HOLLAND JW, HUI C, CULLIS PR, MADDEN TD: Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry (1996) 35:2618–2624.
   PubMed Web of Science ®Google Scholar
• WHEELER JJ, PALMER L, OSSANLOU M et al.: Stabilized plasmid-lipid particles: construction and characterization. Gene Therapy (1999) 6:271–281.
   PubMed Web of Science ®Google Scholar
• MOK KW, LAM AM, CULLIS PR: Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties. Biochim. Biophy Acta (1999) 1419:137–150.
   PubMed Web of Science ®Google Scholar
• SACKMANN E: Membrane bending energy concept of vesicle- and cell-shapes and shape transitions. FEBS Lett. (1994) 346:3–16.
   PubMed Web of Science ®Google Scholar
• LIPOWSKY R: The conformation of membranes. Nature (1991) 349:475–481.
   PubMed Web of Science ®Google Scholar
• RAND RP, KACHAR B, REESE TS: Dynamic morphology of calcium-induced interactions between phosphatidylserine vesicles. Biophys. J. (1985) 47:483–489.
   PubMed Web of Science ®Google Scholar
• KACHAR B, FULLER N, RAND RP: Morphological responses to calcium-induced interactions of phosphatidylserine- containing vesicles. Biophys. J (1986) 50:779–788.
   PubMed Web of Science ®Google Scholar
• HUEBNER S, BATTERSBY BJ, GRIMM R, CEVC G: Lipid-DNA complex formation: reorganization and fusion of lipid bilayers in the presence of DNA as observed by cryo-electron microscopy. Biophys. J. (1999) 76:3158–3166.
   PubMed Web of Science ®Google Scholar
• EVANS EA, PARSEGIAN VA: Energetics of membrane deformation and adhesion in cell and vesicle aggregation. Ann. NY Acad. Sci. (1983) 416:13–33.
   PubMed Web of Science ®Google Scholar
• KOLTOVER I, SALDITT T, RADLER JO, SAFINYA CR: An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delively. Science (1998) 281:78–81.
   PubMed Web of Science ®Google Scholar
• MAURER N, WONG KF, STARK H et aL: Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophysical J (2001) 80:2310–2326.
   PubMed Web of Science ®Google Scholar
• BLUME G, CEVC G: Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta (1990) 1029:91–97.
   PubMed Web of Science ®Google Scholar
• KLIBANOV AL, MARUYAMA K, TORCHILIN VP, HUANG L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. (1990) 268:235–237.
   PubMed Web of Science ®Google Scholar
• PAPAHADJOPOULOS D, ALLEN TM, GAB IZON A et al.: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic activity. Proc. Natl. Acad. Sci. USA (1991) 88:11460–11464.
   Google Scholar
• SENIOR J, DELGADO C, FISHER D, TILCOCK C, GREGORIADIS G: Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from circulation: studies with polyethylene glycol-coated vesicles. Biochim. Biophys. Acta (1991) 1062:77–82.
   PubMed Web of Science ®Google Scholar
• SENIOR JH: Fate and behavior of liposomes in vivo: a review of controlling factors. Grit. Rev. Ther. Drug Carrier Syst. (1987) 3:123–193.
   PubMed Web of Science ®Google Scholar
• PATEL HM: Serum opsonins and liposomes: their interaction and opsonophagocytosis. Grit. Rev. Then Drug Carrier Syst. (1992) 9:39–90.
   PubMed Web of Science ®Google Scholar
• SEMPLE SC, CHONN A, CULLIS PR: Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv. Drug Del. Rev. (1998) 32:3-18. The authors of this review describe how alterations in the physicochemical properties of liposomes influence the interactions with blood proteins and affect the circulation lifetimes.
   Google Scholar
• MAYER LD, CULLIS, PR, BALLY, MB: Designing therapeutically optimized liposomal anticancer delivery systems: lessons from conventional liposomes. In: Medical Applications ofLiposomes. DD Lasic, D Papahadjopoulos (Eds.), Elsevier Science, Amsterdam (1998):231–257.
   Google Scholar
• ••Discuss strategies for the optimisation ofliposomal anticancer drugs. Similar in content to the review by Drummond et a, however, the emphasis lies on conventional liposomal carriers.
   Google Scholar
• DRUMMOND DC, MEYER 0, HONG K, KIRPOTIN DB, PAPAHADJOPOULOS D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. (1999) 51:691–743.
   PubMed Web of Science ®Google Scholar
• ••A good and extensive review on liposomaldrug delivery with emphasis on liposomal doxorubicin. The authors review the current literature on liposomal drug delivery and attempt to show how optimisation of the balance of circulation lifetimes, drug-induced toxicities, accumulation in tumours and drug release rates from liposomes results in the clinically most effective formulations.
   Google Scholar
• ALLEN TM, STUART DD: Liposome pharmacokinetics: classical, sterically stabilized, cationic liposomes and immunoliposomes. In: Liposomes: Rational design. AS Janoff (Ed.), Marcel Dekker Inc, NY (1999):63–87.
   Google Scholar
• MOGHIMI MS, HUNTER CA, MURRAY CJ: Long-circulating and target-specific nanoparticles: theory and practice. Pharmacol. Rev. (2001) 53:283–318.
   PubMed Web of Science ®Google Scholar
• SCHERPHOF G, ROERDINK F, WAITE M, PARKS J: Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim. Biophys. Acta (1978) 542:296–307.
   PubMed Web of Science ®Google Scholar
• KLAUSNER RD, BLUMENTHAL R, INNERARITY T, WEINSTEIN JN: The interaction of apolipoprotein A1 with small unilamellar vesicles of L-alpha-dipalmitoylphosphatidylcholine. J. Biol. Chem. (1985) 260:13719–13727.
   PubMedGoogle Scholar
• MORGAN JR, WILLIAMS LA, HOWARD CB: Technetium-labelled liposome imaging for deep-seated infection. 942
   Google Scholar
• •• Br. J. Radiology (1985) 58:35–39.
   Google Scholar
• GABIZON A, PAPAHADJOPOULOS D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Nail. Acad. Sci. USA (1988) 85:6453–6469.
   Google Scholar
• GABIZON A, PAPAHADJOPOULOS D: The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta (1992) 1103:94–100.
   PubMed Web of Science ®Google Scholar
• GABIZON A, CATANE R, UZIELY B et al.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. (1994) 54:987–992.
   PubMed Web of Science ®Google Scholar
• BOERMAN OC, DAMS ET, OYEN WJ, CORSTENS FH, STORM G: Radiopharmaceuticals for scintigraphic imaging of infection and inflammation. Inflammation Res. (2001) 50:55–64.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev. (1987) 6:559–593.
   PubMed Web of Science ®Google Scholar
• YUAN F, DELLIAN M, FUKUMURA D et al.: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. (1995) 55:3752–3756.
   PubMed Web of Science ®Google Scholar
• STRAUBINGER RM, HONG K, FRIEND DS, PAPAHADJOPOULOS D: Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell (1983) 32:1069–1079.
   PubMed Web of Science ®Google Scholar
• LEE KD, HONG K, PAPAHADJOPOULOS D: Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochi mica Biophysica Acta (1992) 1103:185–197.
   PubMed Web of Science ®Google Scholar
• FRIEND DS, PAPAHADJOPOULOS D, DEBS RJ: Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochimica Biophysica Acta (1996) 1278:41–50.
   PubMed Web of Science ®Google Scholar
• DIJKSTRA J, VAN GALEN M, REGTS D, SCHERPHOF G: Uptake and processing of liposomal phospholipids by Kupffer cells in vitro. Euro. J. Biochem. (1985) 148:391–397.
   PubMedGoogle Scholar
• ALLEN TM, CHONN A: Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. (1987) 223:42–46.
   PubMed Web of Science ®Google Scholar
• ALLEN TM, HANSEN C: Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta (1991) 1066:29–36.
   PubMed Web of Science ®Google Scholar
• WEBB MS, HARASYM TO, MASIN D, BALLY MB, MAYER LD: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer. (1995) 72:896–904.
   PubMed Web of Science ®Google Scholar
• ALLEN TM, HANSEN CB, LOPES DE MENEZES DE: Pharmacokinetics of long-circulating liposomes. Adv. Drug Del. Rev. (1995) 16:267–284.
   Web of Science ®Google Scholar
• LASIC DD, MARTIN F: Stealth Liposomes. CRC Press, Boca Raton, Florida (1995).
   Google Scholar
• BOLARD J: Interaction of polyene antibiotics with membrane lipids: physicochemical studies of the molecular basis of selectivity. Drugs Under Experimental Clinical Res. (1986) 12:613–618.
   PubMedGoogle Scholar
• GRANT CW, HAMILTON KS, HAMILTON KD, BARBER KR: Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment. Biochim. Biophys. Acta (1989) 984:11–20.
   PubMed Web of Science ®Google Scholar
• WASAN KM, LOPEZ-BERESTEIN G: Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur. j Clin. Microbial Infect. Dis. (1997) 16:81–92.
   PubMed Web of Science ®Google Scholar
• MADDEN TD, HARRIGAN PR, TAI LCL et al.: The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids (1990) 53:37–46.
   PubMed Web of Science ®Google Scholar
• HARRIGAN PR, WONG KF, REDELMEIER TE, WHEELER JJ, CULLIS PR: Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim. Biophys. Acta (1993) 1149:329–338.
   PubMed Web of Science ®Google Scholar
• HARAN G, COHEN R, BAR LK, BARENHOLZ Y: Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta (1993) 1151:201–215.
   PubMed Web of Science ®Google Scholar
• FENSKE D, WONG KF, MAURER-SPUREJ E et al.: Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim. Biophy. Acta (1998) 1414:188–204.
   PubMed Web of Science ®Google Scholar
• CULLIS PR, HOPE MJ, BALLY MB, MADDEN TD, MAYER LD, FENSKE DB: Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta (1997) 1331:187–211.
   PubMed Web of Science ®Google Scholar
• ••Good review of the theoretical aspects andpractical applications of pH gradients for the transbilayer transport of drugs, lipids, peptides and metal ions.
   Google Scholar
• CHEUNG BC, SUN TH, LEENHOUTS JM, CULLIS PR: Loading of doxorubicin into liposomes by forming Mn2*-drug complexes. Biochim. Biophys. Acta (1998) 1414:205–216.
   PubMed Web of Science ®Google Scholar
• HARASYM TO, CULLIS PR, BALLY MB:Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes. Cancer Chemotherapy Pharmacal (1997) 40:309–317.
   Google Scholar
• MAURER N, WONG KF, HOPE MJ, CULLIS PR: Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. Biochim. Biophys. Acta (1998) 1374:9–20.
   PubMed Web of Science ®Google Scholar
• LASIC DD, FREDERIK PM, StUART MCA, BARENHOLZ Y, MCINTOSH TJ: Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. (1992) 312:255–258.
   PubMed Web of Science ®Google Scholar
• LASIC DD, CEH B, STUART MCA, GUO L, FREDERIK PM, BARENHOLZ Y: Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta (1995) 1239:145–156.
   PubMed Web of Science ®Google Scholar
• LI X, HIRSH DJ, CABRAL-LILLY D et cd.: Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim. Biophys. Acta (1998) 1415:23–40.
   Google Scholar
• LI X, CABRAL-LILLY D, JANOFF AS, PERKINS WR: Complexation of internalized doxorubicin into fiber bundles affects its release rate from liposomes. E Liposome Res. (2000) 10:15–27.
   Web of Science ®Google Scholar
• MAURER-SPUREJ E, WONG KF, MAURER N, FENSKE D, CULLIS PR: Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles. Biochim. Biophys. Acta (1998) 1416:1–10.
   Web of Science ®Google Scholar
• COWENS JW, CREAVEN PJ, GRECO WR et al.: Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. (1993) 53:2796–2802.
   PubMed Web of Science ®Google Scholar
• NORTHFELT DW, MARTIN FJ, WORKING P et al.: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma./ Clin. Pharmacol. (1996) 36:55–63.
   PubMed Web of Science ®Google Scholar
• BOMAN NL, MASIN D, MAYER LD, CULLIS PR, BALLY MB: Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. (1994) 54:2830–2833.
   PubMed Web of Science ®Google Scholar
• WEBB MS, HARASYM TO, MASIN D, BALLY MB, MAYER LD: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer (1995) 72:896–904.
   PubMed Web of Science ®Google Scholar
• FORSSEN EA: The design and development of DaunoXome® for solid tumor targeting in vivo. Adv. Drug Deliv. Rev. (1997) 24:133–150.
   Web of Science ®Google Scholar
• HOUGHTON AN AND SCHEINBERG DA: Monoclonal antibody therapies - a 'constant' threat to cancer. Nature Med. (2000) 6:373–374.
   PubMed Web of Science ®Google Scholar
• GERASIMOV OV, RUI Y, THOMPSON DH: Triggered release from liposomes mediated by physically and chemically induced phase transitions. In: Vesicles. M Rosoff (Ed.) Marcel-Dekker, NY (1996):679–746.
   Google Scholar
• RUI Y, WANG S, LOW PS, THOMPSON DH: Diplasmenylcholine-folate liposomes: an efficient vehicle for intracellular drug delivery Am. Chem. Soc. (1998) 120:11213–11218.
   Web of Science ®Google Scholar
• QUALLS MM, THOMPSON DH: Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: intracellular localization and synergistic phototoxicity. Int. J. Cancer (2001) 93:384–392.
   PubMed Web of Science ®Google Scholar
• BONDURANT B, MUELLER A, O'BRIEN DF: Photoinitiated destabilization of sterically stabilized liposomes. Biochimica Biophys. Acta. (2001) 1511:113–122.
   PubMed Web of Science ®Google Scholar
• HUANG SK, STAUFFER PR, HONG et al.: Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. (1994) 54:2186–2191.
   PubMed Web of Science ®Google Scholar
• GAB ER MH, WU NZ, HONG K, HUANG SK, DEWHIRST MW, PAPAHADJOPOULOS D: Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Rail. Oncol. Biol. Physics (1996) 36:1177–1187.
   PubMed Web of Science ®Google Scholar
• VAN BREE C, KROOSHOOP JJ, RIETBROEK RC, KIPP JB, BAKKER PJ: Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res. (1996) 56:563–568.
   PubMed Web of Science ®Google Scholar
• KONG G, BRAUN RD, DEWHIRST MW: Hyperthermia enables tumor-specific non-particle delivery: effect of particle size. Cancer Res. (2000) 60:4440–4445.
   PubMed Web of Science ®Google Scholar
• KONG G, ANYARAMBHATLA G, PETROS WP et al.: Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. (2000) 60:6950–6957.
   PubMed Web of Science ®Google Scholar
• NEEDHAM D, ANYARAMBHATLA G, KONG G, DEWHIRST MW: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. (2000) 60:1197–1201.
   PubMed Web of Science ®Google Scholar
• MASTROBATTISTA E, KONING GA, STORM G: Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Deliv. Rev. (1999) 40:103–127.
   PubMed Web of Science ®Google Scholar
• ••Good review on immunoliposomes.Describes problems associated with antibody targeting and tries to point out potential solutions.
   Google Scholar
• DRUMMOND DC, HONG K, PARK JW, BENZ CC, KIRPOTIN DB: Liposome targeting to tumors using vitamin and growth factor receptors. Vitamins Hormones (2000) 60:285–332.
   PubMed Web of Science ®Google Scholar
• MARUYAMA K: In vivo targeting by liposomes. Biological Pharmaceut. Bull. (2000) 23:791–799.
   PubMed Web of Science ®Google Scholar
• ALLEN TM, BRANDEIS E, HANSEN CB, KAO GY, ZALIPSKY S: A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta (1995) 1237:99–108.
   PubMed Web of Science ®Google Scholar
• HARDING JA, ENGBERS CM, NEWMAN MS, GOLDSTEIN NI, ZALIPSKY S: Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim. Biophys. Acta (1997) 1327:181–192.
   PubMed Web of Science ®Google Scholar
• BLUME G, CEVC G, CROMMELIN MD, BAKKER-WOUDENBERG IA, KLUFT C, STORM G: Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta (1993) 1149:180–184.
   PubMed Web of Science ®Google Scholar
• HANSEN CB, KAO GY, MOASE EH, ZALIPSKY S, ALLEN TM: Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta (1995) 1239:133–144.
   PubMed Web of Science ®Google Scholar
• MARUYAMA K, TAKIZAWA T, TAKAHASHI N, TAGAWA T, NAGAIKE K, IWATSURU M: Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv. Drug Del. Rev. (1997) 24:235–242.
   Web of Science ®Google Scholar
• ZALIPSKY S, PUNTAMBEKAR B, BOULIKAS P, ENGBERS CM, WOODLE MC: Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR. Bioconjugate Chem. (1995) 6:705–708.
   PubMed Web of Science ®Google Scholar
• ZALIPSKY S, MULLAH N, HARDING JA, GITTELMAN J, GUO L, DEFREES SA: Poly(ethylene glycol) -graftedliposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjugate Chem. (1997) 8:111–118.
   PubMed Web of Science ®Google Scholar
• GABIZON A, HOROWITZ AT, GOREN D et al.: Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem. (1999) 10:289–298.
   PubMed Web of Science ®Google Scholar
• USTER PS, ALLEN TM, DANIEL BE, MENDEZ CJ, NEWMAN MS, ZHU GZ: Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. (1996) 386:243–246.
   PubMed Web of Science ®Google Scholar
• SOU K, ENDO T, TAKEOKA S, TSUCHIDA E: Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjugate Chem. (2000) 11:372–379.
   PubMed Web of Science ®Google Scholar
• FENSKE DB, PALMER LP, CHEN T, WONG KF, CULLIS PR: Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding
   Google Scholar
• •• and uptake to BHK cells. Biochim. Biophys. Acta (2000:1–14.
   Google Scholar
• IDEN DL, ALLEN TM: In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta (2001) 1513:207–216.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G, NEERUNJUN DE: Homing of liposomes to target cells. Biochem. Biophys. Res. Comm. (1975) 65:537–544.
   PubMed Web of Science ®Google Scholar
• PHILLIPS NC, EMILI A: Immunogenicity of immunoliposomes. Immunol Lett. (1991) 30:291–296.
   PubMed Web of Science ®Google Scholar
• PHILLIPS NC, DAHMAN J: Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Immunol Lett. (1995) 45:149–152.
   PubMed Web of Science ®Google Scholar
• SUGANO M, EGILMEZ NK, YOKOTA SJ et al.: Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. (2000) 60:6942–6949.
   PubMed Web of Science ®Google Scholar
• MARUYAMA K, TAKAHASHI N, TAGAWA T, NAGAIKE K, IWATSURU M: Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. (1997) 413:177–180.
   PubMed Web of Science ®Google Scholar
• PARK JW, HONG K, KIRPOTIN DB, MEYER 0, PAPAHADJOPOULOS D, BENZ CC: Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. (1997) 118:153–160.
   PubMed Web of Science ®Google Scholar
• LAUKKANEN ML, ALFTHAN K, KEINANEN K: Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. Biochemistry (1994) 33:11664–11670.
   PubMed Web of Science ®Google Scholar
• DE KRUIF J, STORM G, VAN BLOOIS L, LOGTENBERG T: Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett. (1996) 399:232–236.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Barriers to drug delivery in solid tumors. Scientific Am. (1994) 271:58–65.
   PubMed Web of Science ®Google Scholar
• HUANG SK, LEE K-D, HONG K, FRIEND DS, PAPAHADJOPOULOS D: Microscopic localization of sterically stabilized liposomes in colon carcinoma- bearing mice. Cancer Res. (1992) 52:5135–5143.
   PubMed Web of Science ®Google Scholar
• YUAN F, LEUNIG M, HUANG SK, BERK DA, PAPAHADJOPOULOS D, JAIN RK: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. (1994) 54:3352–3356.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Fighting cancer by attacking its blood supply. Scientific Am. (1996) 275:150–154.
   PubMed Web of Science ®Google Scholar
• FIDLER IJ: Angiogenesis and cancer metastasis. Cancer J Scientific Am. (2000) 6\(Suppl. 2):5134–141.
   Google Scholar
• ARAP W, PASQUALINI R, RUOSLAHTI E: Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol (1998) 10:560–565.
   PubMedGoogle Scholar
• FOLKMAN J: Angiogenic zip code. Nature Biotech. (1999) 17:749.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E: Targeting tumor vasculature with homing peptides from phage display. Sem. Cancer Biol. (2000)10:435–442.
   PubMed Web of Science ®Google Scholar
• HUANG X, MOLEMA G, KING S, WATKINS L, EDGINGTON TS, THORPE PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (1997) 275:547–550.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279:377–380.
   PubMed Web of Science ®Google Scholar
• TRAIL PA, BIANCHI AB: Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol (1999) 11:584–588.
   PubMed Web of Science ®Google Scholar
• NILSSON F, TARLI L, VITT F, NERI D: The use of phage display for the developments of tumor targeting agents. Adv. Drug Deliv. Rev. (2000) 43:165–196.
   PubMed Web of Science ®Google Scholar
• RAMAKRISHNAN S, WILD R, NOJIMA D: Targeting tumor vasculature using VEGF-toxin conjugates. Methods Malec. Biol. (2001) 166:219–234.
   PubMedGoogle Scholar
• ALLISON AC, GREGORIADIS G: Liposomes as immunological adjuvants. Nature (1974) 252:252.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G: Liposomes as immunological adjuvants for protein and peptide vaccines. In: Liposomes in Biomedical Applications. PN Shek (Ed.), Harwood Academic Press, US (1995):1–18.
   Google Scholar
• DAEMEN T, HOEDEMAKERS R, STORM G, SCHERPHOF GL: Opportunities in targeted delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells - activation of tumoricidal properties. Adv. Drug Deliv. Rev. (1995) 17:21–30.
   Web of Science ®Google Scholar
• ALVING CR: Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann. NY Acad. Sci. (1995) 754:143–152.
   PubMed Web of Science ®Google Scholar
• KILLION JJ, FIDLER IJ: Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators. Pharmacol Therapeut. (1998) 78:141–154.
   PubMed Web of Science ®Google Scholar
• ••This review summarises approaches toimmunotherapy for cancer, which involve liposome-associated macrophage activators such as muramyldipeptide and MTP-PE, a lipophilic derivative thereof. The cellular mechanisms of macrophage-directed antitumor therapy are discussed and an overview of recent clinical trials is presented.
   Google Scholar
• RAO M, ALVING CR: Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Deliv. Rev. (2000) 41:171–188.
   PubMed Web of Science ®Google Scholar
• ••Review of the cellular fate of liposomalantigen, in particular, the mechanism of entry of liposome-encapsulated antigens into the MHC class I pathway, which results in the activation of cytotoxic T-cell responses.
   Google Scholar
• BURKHARD L, BARCHIESI F, PERICIN M, ZINKERNAGEL RM, HENGARTNER H, SCHWENDERER RA: In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and antitumor immunity. Vaccine (2001) 19:23–32.
   Web of Science ®Google Scholar
• VOGEL FR, POWELL MF, ALVING CR: A compendium of vaccine adjuvants and excipients. (2001) Available at: www.niaid.nih.gov/daids/vaccine/ adjuvants.htm.
   Google Scholar
• ZHOU F, HUANG L: Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway. Immunomethods (1994) 4:229–235.
   PubMedGoogle Scholar
• GLUCK R: Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine (1999) 17:1782–1787.
   PubMed Web of Science ®Google Scholar
• GLUCK R, WALTI E: Biophysical validation of Epaxal Berna, a hepatitis A
   Google Scholar
• •• vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Develop. Biologicals (2000) 103:189–197.
   Google Scholar
• GREGORIADIS G: Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol (1995) 13:527–537.
   PubMed Web of Science ®Google Scholar
• VOSIKA GJ, CORNELIUS DA, GILBERT CW et al.: Phase I trial of ImmThere, a new liposome-incorporated lipophilic disaccharide tripeptide. Immunotherapy (1991) 10:256–266.
   PubMed Web of Science ®Google Scholar
• LACHMAN LB, SHIH LC, RAO XM, ULLRICH SE, CLELAND JL: Cytokine-containing liposomes as adjuvants for subunit vaccines. Pharmaceut. Biotechnol (1995) 6:659–671.
   PubMedGoogle Scholar
• EUE I, KUMAR, R, DONG Z, KILLION JJ, FIDLER IJ: Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes.j Immunother. (1998) 21:340–351.
   PubMed Web of Science ®Google Scholar
• WORTH LL, JIA S-F, ANT, KLEINERMAN ES: ImmThere, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother. (1999) 48:312–320.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G, MCCORMACK B, OBRENOVIC M, PERRIE Y, YANG JC: Genetic vaccines: a role for liposomes. In: Targeting of Drugs: Strategies for gene Constructs and Delivery G Gregoriadis, B McCormack (Eds.), NATO Science Series Vol. 323, IOS Press, Amsterdam (2000):92–101.
   Google Scholar
• MOINGEON P: Cancer vaccines. Vaccine (2001) 19:1305–26.
   PubMed Web of Science ®Google Scholar
• SJOLANDER A, COX JC, BARR IG: ISCOMs: an adjuvant with multiple functions. J Leukocyte Biol. (1998) 64:713–723.
   PubMed Web of Science ®Google Scholar
• SJOLANDER A, DRANE D, MARASKOVSKY E et al.: Immune responses to ISCOM formulations in animal and primate models. Vaccine (2001) 19:2661–2665.
   PubMed Web of Science ®Google Scholar
• WALLACH DFH, PHILIPPOT JR: New type of lipid vesicle. NovasomeTM. In: Liposome Technology: Lzposome Preparation and Related Techniques. G Gregoriadis (Ed.), CRC Press, Boca Raton, Florida, USA (1993):141–156.
   Google Scholar
• GUPTA RK, VARANELLI CL, GRIFFIN P, WALLACH DF, SIBER GR: Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens. Vaccine (1996) 14:219–225.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Gene therapy for cancer. In: Textbook of Gene Therapy. Hogrefe and Huber Publishers, Seattle (1998):117–160.
   Google Scholar
• ••A good summary of the current approachesfor gene therapy of cancer with a lot of background information on the general concepts.
   Google Scholar
• MORSE MA: Technology evaluation: gene therapy (IL-2), Valentis, Inc. Curr. Opin. Malec. Therapeut. (2000) 2:448–452.
   PubMed Web of Science ®Google Scholar
• PACHUK CJ, MCCALLUS DE, WEINER DB, SATISHCHANDRAB C: DNA vaccines - challenges in delivery. Curr. Opin. Malec. Therapeut. (2000) 2:188–198.
   PubMed Web of Science ®Google Scholar
• THE JOURNAL OF GENE MEDICINE Clinical Trial Site. This site is available at http://www.wiley.com/legacy/wileychi-genmed/clinical/.
   Google Scholar
• ••Provides a very comprehensive list of genetherapy trials. The charts and tables show the number of protocols and patients in ongoing and completed clinical trials worldwide. Last updated in Febuary 2001.
   Google Scholar
• BONNET MC, TARTAGLIA J, VERDIER F et al.: Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett. (2000) 74:11–25.
   PubMed Web of Science ®Google Scholar
• SEMPLE SC, KLIMUK SK, HARASYM TO et al.: Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta (2001) 1510:152–166.
   PubMed Web of Science ®Google Scholar
• TAN Y, LI S, PITT BR, HUANG L: The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Then (1999) 10:2153–2161.
   PubMed Web of Science ®Google Scholar
• YEW NS, ZHAO H, WU IH et al.: Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mal Then (2000) 1:255–262.
   PubMed Web of Science ®Google Scholar
• KRIEG AM, YT A-K, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B cell activation. Nature (1995) 374:546–549.
   PubMed Web of Science ®Google Scholar
• BIRD AP: Functions for DNA methylation in vertebrates. Cold Spring Harbor Symposia on Quantitative Biology (1993) 58:281–285.
   PubMedGoogle Scholar
• KRIEG AM, YT A-K, HARTMANN G: Mechanism and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. (1999) 84:113–120.
   PubMed Web of Science ®Google Scholar
• ••Describes the immune effects andmechanisms of action of CpG DNA/ motifs and their applications for therapeutic vaccination.
   Google Scholar
• KRIEG AM: Minding the Cs and Gs. Malec. Therapy (2000) 1:209–210.
   PubMed Web of Science ®Google Scholar
• KRIEG A: Immune effects and mechanisms of action of CpG motifs. Vaccine (2001) 19:618–622.
   Web of Science ®Google Scholar
• KAWABATA K, TAKAKURA Y, HASHIDA M: The fate of plasmid DNA after intravenous injection into mice: involvement of scavenger receptors in its hepatic uptake. Pharmaceut. Res. (1995) 12:825–830.
   PubMed Web of Science ®Google Scholar
• MOUNTAIN A: Gene therapy: the first decade. TIBTECH (2000) 18:119–128.
   PubMed Web of Science ®Google Scholar
• ••This review summarises gene therapyapproaches, results achieved, lessons learned and important recent developments.
   Google Scholar
• LEHRMAN S: Virus treatment questioned after gene therapy death. Nature (1999) 401:517–518.
   PubMed Web of Science ®Google Scholar
• JAIN KK: A Special Report on Gene Therapy Companies. John Wiley & Sons, NY (2000).
   Google Scholar
• FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA (1987) 84:7413–7417.
   PubMed Web of Science ®Google Scholar
• ••Marks the birth of cationic liposome-mediated transfection.
   Google Scholar
• FELGNER PL: Progress in gene delivery research and development. In: Nonviral Vectors for Gene Therapy. L Huang, M Hung, E Wagner (Eds.), Academic Press, NY (1999):25–38.
   Google Scholar
• BARRON LG, SZOKA FC: The perplexing delivery mechanism of lipoplexes. In: Nonviral Vectors for Gene Therapy. L Huang, M Hung, E Wagner (Eds.), Academic Press, NY (1999):229–266.
   Google Scholar
• MAURER N, MORI A, PALMER Let al.: Lipid-based systems for the intracellular delivery of genetic drugs. Malec. Membr. Biol. (1999) 16:129–140.
   Google Scholar
• CHESNOY S, HUANG L: Structure and function of lipid-DNA complexes for gene delivery. Ann. Rev. Biophys. Biomolec. Struct. (2000) 29:27–47.
   PubMedGoogle Scholar
• SORGI FL, HUANG L: Drug delivery
   Google Scholar
• •• applications. In: Lipid Polymorphism and Membrane Properties. Current Topics in Membranes 44, R Epand (Ed.), Academic Press, San Diego, CA (1997):403–445.
   Google Scholar
• XU Y, HUT SW, FREDERIK P, SZOKA FCJ: Physicochemical characterization and purification of cationic lipoplexes. Biophys. J. (1999) 77:341–353.
   PubMed Web of Science ®Google Scholar
• ••Shows how the physicochemical propertiesof lipoplexes such as size and zeta potential as well as their transfection potency change as the positive-to-negative charge ratio is varied.
   Google Scholar
• GUSTAFSSON J, ARVIDSON G, KARLSSON G, ALMGREN M: Complexes between cationic liposomes and DNA visualized by cryo-TEM. Biochim. Biophys. Acta (1995) 1235:305–312.
   PubMed Web of Science ®Google Scholar
• LASIC DD: Liposomes in Gene Delivery CRC Press, Boca Raton (1997):120–140.
   Google Scholar
• RADLER J, KOLTOVER I, JAMIESON A, SALDITT T, SAFINYA CR: Structure and interfacial aspects of self-assembled cationic lipid-DNA gene carrier complexes. Langmuir (1998) 14:4272–4283.
   Web of Science ®Google Scholar
• STERNBERG B, HONG K, ZHENG W, PAPAHADJOPOULOS D: Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo. Biochim. Biophys. Acta (1998) 1375:23–35.
   PubMed Web of Science ®Google Scholar
• LI S, TSENG WC, STOLZ DB, WU SP, WATKINS SC, HUANG L: Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene Therapy (1999) 6:585–594.
   PubMed Web of Science ®Google Scholar
• ZABNER J, FASBENDER AJ, MONINGER T, POELLINGER KA, WELSH MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. (1995) 270:18997–19007.
   PubMed Web of Science ®Google Scholar
• XU Y, SZOKA FC: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 35:5616–5623.
   PubMed Web of Science ®Google Scholar
• LIU Y, MOUNKES LC, LIGGITT HD et al.: Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nature Biotechnol. (1997) 15:167–173.
   PubMed Web of Science ®Google Scholar
• LIU F, QI H, HUANG L, LIU D: Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Then (1997) 4:517–523.
   PubMed Web of Science ®Google Scholar
• TEMPLETON NS, LASIC DD, FREDERIK PM, STREY HH, ROBERTS DD, PAVLAKIS GN: Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnol. (1997) 15:647–652.
   PubMed Web of Science ®Google Scholar
• MCLEAN JW, THURSTON G, MCDONALD DM: Sites of uptake and expression of cationic liposome/DNA complexes injected intravenously. In: Nonviral Vectors for Gene Therapy L Huang, M Hung, E Wagner (Eds.), Academic Press NY (1999):119.
   Google Scholar
• HUANG L, LI S: Liposomal gene delivery: a complex package. Nature Biotechnol. (1997) 15:620–621.
   PubMed Web of Science ®Google Scholar
• ALTON EW, GEDDES DM, GILL DR et al.: Towards gene therapy for cystic fibrosis: a clinical progress report. Gene Ther. (1998) 5:291–292.
   PubMed Web of Science ®Google Scholar
• JAFFE A, JUDD D, RATCLIFFE C et al.: Cationic lipid-mediated gene transfer to the growing murine and human airway. Gene Therapy (2000) 7:273–278.
   PubMed Web of Science ®Google Scholar
• TAMP, MONCK M, LEE D et al.: Stabilized plasmid-lipid particles for systemic gene therapy. Gene Therapy (2000) 7:1867–1874.
   PubMed Web of Science ®Google Scholar
• SARAVOLAC EG, LUDKOVSKI 0, SKIRROW R et al.: Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity. J. Drug Targeting (2000) 7:423–437.
   Google Scholar
• GAO X, HUANG L: Cytoplasmic expression of a reporter gene by co-delivety
   Google Scholar